DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Empire Life Investments Inc.

Empire Life Investments Inc. lifted its stake in DexCom, Inc. (NASDAQ:DXCM) by 6.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 89,263 shares of the medical device company’s stock after purchasing an additional 5,537 shares during the quarter. Empire Life Investments Inc.’s holdings in DexCom were worth $6,942,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in DXCM. Exchange Traded Concepts LLC lifted its holdings in shares of DexCom by 39.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 12,276 shares of the medical device company’s stock worth $823,000 after acquiring an additional 3,474 shares during the last quarter. Creative Planning lifted its holdings in shares of DexCom by 22.3% in the 3rd quarter. Creative Planning now owns 59,573 shares of the medical device company’s stock worth $3,994,000 after acquiring an additional 10,880 shares during the last quarter. Swedbank AB lifted its holdings in shares of DexCom by 15.2% in the 3rd quarter. Swedbank AB now owns 213,864 shares of the medical device company’s stock worth $14,337,000 after acquiring an additional 28,289 shares during the last quarter. Vontobel Holding Ltd. lifted its holdings in shares of DexCom by 92.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 70,586 shares of the medical device company’s stock worth $4,732,000 after acquiring an additional 33,820 shares during the last quarter. Finally, Teamwork Financial Advisors LLC acquired a new position in shares of DexCom in the 3rd quarter worth approximately $839,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

DXCM has been the topic of several recent research reports. Wells Fargo & Company upped their target price on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. JPMorgan Chase & Co. upped their target price on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Citigroup upped their target price on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Finally, Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $99.06.

DexCom Trading Up 5.9 %

NASDAQ DXCM opened at $89.07 on Friday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The firm’s fifty day moving average price is $82.21 and its 200 day moving average price is $75.25. The company has a market capitalization of $34.79 billion, a price-to-earnings ratio of 53.34, a price-to-earnings-growth ratio of 2.26 and a beta of 1.14. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 17.22% and a return on equity of 31.40%. On average, sell-side analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

Insider Activity at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. This represents a 2.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,342 shares of company stock valued at $3,628,069 in the last ninety days. Insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.